Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | DUT | P33316 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14611842 | 1.00 | RIPK1 (0.34) | RIPK1DUTCYP2D6CYP1A2PKM | |
| SCHEMBL14576377 | 1.00 | RIPK1 (0.34) | RIPK1DUTCYP2D6CYP1A2PKM | |
| SCHEMBL6598638 | 0.86 | GABBR2 (0.39) | TAAR1 | |
| SCHEMBL17354844 | 0.84 | TAAR1 (0.39) | CYP2D6TAAR1MAPT | |
| SCHEMBL23199871 | 0.83 | PRKCA (0.41) | RIPK1CYP2D6CYP1A2PKMSMN1; SMN2 | |
| SCHEMBL8330699 | 0.83 | PRKCA (0.41) | RIPK1CYP2D6CYP1A2PKMSMN1; SMN2 | |
| SCHEMBL20278757 | 0.83 | GABBR2 (0.41) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL12487435 | 0.81 | SCN4A (0.40) | — | |
| SCHEMBL6504637 | 0.81 | SCN4A (0.40) | — | |
| SCHEMBL6504640 | 0.81 | SCN4A (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173139-B2 | Enantioselective 1,4-addition of aromatic nucleophiles to α,β-unsaturated aldehydes using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20030236438-A1 | Enantioselective 1,4-addition of aromatic nucleophiles to alpha,beta-unsaturated aldehydes using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236438-A1 | Enantioselective 1,4-addition of aromatic nucleophiles to alpha,beta-unsaturated aldehydes using chiral organic catalysts | NAT1, AOX1, ALDH7A1 | RIPK1 4551/4885DUT 30/4885CYP2D6 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.